The differential expression of MYO6 and GOLM1 in AA prostate cancer tissue suggests transport of RTK proteins and the resulting oncogenic activity of Akt might be a good target to treat the AA aggressive prostate cancer phenotype. The gene discussed is AKT1; the disease is prostate carcinoma.